2018-30年全球2型糖尿病胰岛素使用量预估:微观模拟分析
该研究基于221个国家2018-2030年的2型糖尿病患病率预测和14项队列研究的HbA1c、治疗及体重数据,构建微观模拟模型。
核心结论
- 2018至2030年全球2型糖尿病所需胰岛素量预计增长超过20%。
- 对老年患者采用更高的HbA1c目标可能避免更多DALY。
- 改善胰岛素可及性并实现HbA1c≤7%可显著增加胰岛素使用并避免DALY。
研究设计与样本
- 基于221个国家2018-2030年2型糖尿病患病率预测的微观模拟研究。
- 患病率数据来自国际糖尿病联盟,HbA1c、治疗和体重数据来自14项队列研究,覆盖全球2型糖尿病人口60%以上。
临床怎么用
- 应预计全球2型糖尿病胰岛素需求将持续增长,需提前规划胰岛素供应与可及性。
- 对老年(75岁及以上)2型糖尿病患者可考虑较宽松的HbA1c目标(如8%)以减少低血糖并增加DALY避免。
- 改善胰岛素可及性并实现HbA1c≤7%可显著增加胰岛素使用并避免DALY。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The amount of insulin needed to effectively treat type 2 diabetes worldwide is unknown. It also remains unclear how alternative treatment algorithms would affect insulin use and disability-adjusted life-years (DALYs) averted by insulin use, given that current access to insulin (availability and affordability) in many areas is low. The aim of this study was to compare alternative projections for and consequences of insulin use worldwide under varying treatment algorithms and degrees of insulin access. METHODS: We developed a microsimulation of type 2 diabetes burden from 2018 to 2030 across 221 countries using data from the International Diabetes Federation for prevalence projections and from 14 cohort studies representing more than 60% of the global type 2 diabetes population for HbA1c, treatment, and bodyweight data. We estimated the number of people with type 2 diabetes expected to use insulin, international units (IU) required, and DALYs averted per year under alternative treatment algorithms targeting HbA1c from 6·5% to 8%, lower microvascular risk, or higher HbA1c for those aged 75 years and older. FINDINGS: The number of people with type 2 diabetes worldwide was estimated to increase from 405·6 million (95% CI 315·3 million-533·7 million) in 2018 to 510·8 million (395·9 million-674·3 million) in 2030. On this basis, insulin use is estimated to increase from 516·1 million 1000 IU vials (95% CI 409·0 million-658·6 million) per year in 2018 to 633·7 million (500·5 million-806·7 million) per year in 2030. Without improved insulin access, 7·4% (95% CI 5·8-9·4) of people with type 2 diabetes in 2030 would use insulin, increasing to 15·5% (12·0-20·3) if insulin were widely accessible and prescribed to achieve an HbA1c of 7% (53 mmol/mol) or lower. If HbA1c of 7% or lower was universally achieved, insulin would avert 331 101 DALYs per year by 2030 (95% CI 256 601-437 053). DALYs averted would increase by 14·9% with access to newer oral antihyperglycaemic drugs. DALYs averted would increase by 44·2% if an HbA1c of 8% (64 mmol/mol) were used as a target among people aged 75 years and older because of reduced hypoglycaemia. INTERPRETATION: The insulin required to treat type 2 diabetes is expected to increase by more than 20% from 2018 to 2030. More DALYs might be averted if HbA1c targets are higher for older adults. FUNDING: The Leona M and Harry B Helmsley Charitable Trust.
引用
- Basu S, Yudkin JS, Kehlenbrink S, et al. Estimation of global insulin use for type 2 diabetes, 2018-30: a microsimulation analysis. Lancet Diabetes Endocrinol. 2018. PMID: 30470520. doi:10.1016/S2213-8587(18)30303-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。